Clinical Trials on Non-small-cell Lung Cancer (NSCLC)

Total 7928 results

AstraZeneca

Completed

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC)

Non - Small Cell Lung Cancer NSCLC

United States, France, Germany, Italy, United Kingdom, Belgium, Poland, Romania, Taiwan, Thailand, Canada, Korea, Republic of, Czechia, Hungary, Japan, Russian Federation, Hong Kong, Spain, Netherlands, Greece, Australia, Serbia, Bu... and more
Incyte Corporation

Terminated

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

NSCLC (Non-small Cell Lung Carcinoma)

United States
Incyte Corporation

Terminated

Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

NSCLC (Non-small Cell Lung Carcinoma)

United States
Alexander Chi

Not yet recruiting

Combining ICI With SBRT or HypoFrx-RT for ES NSCLC

Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage II

China
National Cancer Institute (NCI)

Terminated

Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection

Stage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Not yet recruiting

Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy

Stage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

Canada
Karen Kelly
Bristol-Myers Squibb; National Cancer Institute (NCI); Transgene

Completed

TG4010 and Nivolumab in Patients With Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer

United States
Navire Pharma Inc., a BridgeBio company
Amgen

Recruiting

SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation (Argonaut)

Non Small Cell Lung Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Metastatic NSCLC

Spain, Australia, France, Denmark, Greece, Italy, Netherlands
University Hospital, Essen
German Cancer Aid

Not yet recruiting

Exercise in Patients With Advanced Non-small Cell Lung Cancer (BREATH)

Advanced Lung Carcinoma | NSCLC Stage IV | NSCLC Stage IIIB | First Line Treatment | Second Line Treatment | Palliative Treatment | NSCLC Stage IIIC

Germany
Centre René Gauducheau

Completed

TF2- Small Cell Lung Cancer Radio Immunotherapy

Small Cell Lung Cancer | CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)

France
Sun Yat-sen University

Recruiting

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

Non-small Cell Lung Cancer (NSCLC) | EGFR-TKI Resistant Mutation | EGFR-TKI Sensitizing Mutation | Somatic Mutation | Germline Mutations

China
Eikon Therapeutics

Recruiting

A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer

NSCLC

United States
Northern Jiangsu Province People's Hospital

Recruiting

A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer

NSCLC

China
Energenx Medical LTD.

Recruiting

Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer

NSCLC

China
Canadian Cancer Trials Group
Novartis

Recruiting

Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer

NSCLC

Canada
InventisBio Co., Ltd

Recruiting

A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer

NSCLC

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of HA121-28 in Patients With Non-Small Cell Lung Cancer

NSCLC

China
Shanghai Henlius Biotech

Recruiting

A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation

NSCLC

China
Guangdong Association of Clinical Trials

Unknown

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

Nsclc
Allist Pharmaceuticals, Inc.

Unknown

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer

NSCLC
Henan Cancer Hospital
Cttq

Unknown

Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer

NSCLC

China
Hutchison Medipharma Limited

Completed

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

NSCLC

China
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in Non-Small Cell Lung Cancer (NSCLC): Pilot Study (IMAHTEP)

NSCLC

France
HiberCell, Inc.

Completed

Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

NSCLC

United States, Germany
Pierre Fabre Medicament
Pierre Fabre Pharma GmbH

Completed

Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer

NSCLC

Germany
Nanfang Hospital of Southern Medical University

Unknown

Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer

NSCLC

China
Yuhan Corporation
The Korean Academy of Tuberculosis and Respiratory Diseases

Recruiting

Korean Registry of Non-Small Cell Lung Cancer Patients With EGFR Mutation

NSCLC

Korea, Republic of
Peking University Cancer Hospital & Institute
Geneplus-Beijing Co. Ltd.

Recruiting

Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer (MRDinS3LC)

NSCLC

China
Hunan Province Tumor Hospital

Not yet recruiting

A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer

NSCLC

China
Shanghai Chest Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

NSCLC

China
Oslo University Hospital
St. Olavs Hospital

Recruiting

Drug Concentration Monitoring of Pembrolizumab in Non-Small Cell Lung Cancer Patients (Oncomabs)

NSCLC

Norway
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

NSCLC
Kura Oncology, Inc.

Withdrawn

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

NSCLC

United States
Qian Chu

Completed

A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC)

NSCLC

China
Hutchison Medipharma Limited

Completed

A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer (FALUCA)

NSCLC

China
Betta Pharmaceuticals Co., Ltd.

Unknown

High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (INCREASE)

NSCLC

China
Shanghai Chest Hospital

Unknown

Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer

NSCLC

China
GlobeImmune
Memorial Sloan Kettering Cancer Center

Completed

A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation

NSCLC

United States
Sheba Medical Center

Unknown

An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

NSCLC

Israel
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients

NSCLC

United States
Symphogen A/S

Completed

Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies

NSCLC | Non Small Cell Lung Cancer | Oncology | MET Gene Mutation | MET Gene Amplification

United States, Korea, Republic of, Denmark, Hong Kong, Taiwan, Spain
Syndax Pharmaceuticals

Completed

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer (ENCORE110)

Breast Cancer | Lung Cancer | Non Small Cell Lung Cancer (NSCLC) | Estrogen Receptor Breast Cancer

United States
Pfizer

Completed

Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung (NSCLC)

Ukraine, Poland, Romania, South Africa
Virginia Commonwealth University
National Cancer Institute (NCI)

Withdrawn

Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

United States
MedImmune LLC

Completed

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

NSCLC | Resectable | Early-stage

United States, Canada, Switzerland, Italy, France, Portugal, Spain
A2 Biotherapeutics Inc.
Tempus AI

Recruiting

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression (EVEREST-1)

Cancer | Colorectal Neoplasms | Colorectal Cancer | Pancreatic Neoplasms | Pancreatic Cancer | NSCLC | Solid Tumor | Non Small Cell Lung Cancer | Colorectal Cancer Metastatic | Pancreas Cancer | Colorectal Adenocarcinoma | Solid Tumor, Adult | CRC | NSCLC, Recurrent | Non Small Cell Lung Cancer Recurrent | Non-Small Cell...

United States
Novartis Pharmaceuticals

Available

Managed Access Programs for LDK378, Ceritinib

Non-small Cell Lung Cancer (NSCLC) | Anaplastic Lymphoma Kinase (ALK)- Positive Tumors
National Cancer Center, China

Not yet recruiting

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations (EGFR)

NSCLC
Henan Provincial People's Hospital

Not yet recruiting

Efficacy and Safety of Microwave Ablation Combined With Camrelizumab and Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer: a Multicenter, Open, Prospective Study (NSCLC)

Nsclc
Tang-Du Hospital

Not yet recruiting

Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer (pcwaintrl)

NSCLC

Clinical Trials on Non-small-cell Lung Cancer (NSCLC)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations